June 8, 2020 / 8:13 PM / a month ago

BRIEF-Soleno Therapeutics Announces Top-Line Results From Phase III Trial Of DCCR For Treatment Of Prader-Willi Syndrome

June 8 (Reuters) - Soleno Therapeutics Inc:

* SOLENO THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PHASE III TRIAL OF DCCR FOR TREATMENT OF PRADER-WILLI SYNDROME

* SOLENO THERAPEUTICS INC - STUDY DID NOT MEET STATISTICAL SIGNIFICANCE FOR PRIMARY ENDPOINT

* SOLENO THERAPEUTICS INC - STUDY SHOWED SIGNIFICANT IMPROVEMENTS IN PRESPECIFIED SUBGROUP WITH SEVERE HYPERPHAGIA

* SOLENO THERAPEUTICS INC - SIGNIFICANT POSITIVE CHANGES ALSO SEEN IN TWO OF THREE KEY SECONDARY ENDPOINTS

* SOLENO - INTERIM ANALYSIS OF ONGOING EXTENSION STUDY SHOWED FURTHER REDUCTIONS IN HYPERPHAGIA OF 48% AFTER SIX MONTHS OF DCCR TREATMENT

* SOLENO THERAPEUTICS - CONTINUING TO EVALUATE DATA FROM C601. C602; PLAN TO MEET REGULATORY AUTHORITIES TO DETERMINE NEXT STEPS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below